Medine.co.uk

Birp Oral Emulsion For Cattle

Revised: September 2016

AN: 00798/2016


SUMMARY OF PRODUCT CHARACTERISTICS


1.

NAME OF THE VETERINARY MEDICINAL PRODUCT


Birp Oral Emulsion for Cattle

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION


Active substance

Qualitative composition

Simethicone


Excipients

Sodium propyl hydroxybenzoate

Sodium methyl hydroxybenzoate


For a full list of excipients, see section 6.1.


Quantitative composition % w/v

1.00


0.05

0.15


3.

PHARMACEUTICAL FORM


Oral emulsion.

A white emulsion of Simethicone.

4.

CLINICAL PARTICULARS

4.1

Target species


Cattle.

4.2

Indications for use, specifying the target species


For the relief of gaseous and frothy bloat in cattle.

4.3

Contraindications


None known.


4.4

Special warnings for each target species


Secondary or free-gas bloat most often occurs in single animals, in which there is obstruction of eructation. In such cases, treatment should be supported by veterinary diagnosis of the cause of the failure of eructation.

In outbreaks of primary frothy bloat, management strategies should be introduced to reduce foam production in the rumen or to control access of cattle to pasture or grains that promote excess gaseous foams.



4.5

Special precautions for use

i.

Special precautions for use in animals


Use the container on one occasion only; discard it and any remaining contents after use.


ii.

Special precautions for the person administering the veterinary medicinal product to animals


Wash hands after use.

4.6

Adverse reactions (frequency and seriousness)


None known.

4.7

Use during pregnancy, lactation or lay


No special precautions.

4.8

Interaction with other medicinal products and other forms of interaction


None known.

4.9

Amount(s) to be administered and administration route


By oral administration, 50 to 100 ml. A second dose may be given 3 hours later if required.

4.10

Overdose (symptoms, emergency procedures, antidotes), if necessary


Not known.

4.11

Withdrawal period(s)


Meat: Zero days

Milk: Zero hours

5.

PHARMACOLOGICAL PROPERTIES



Pharmacotherapeutic group



Other alimentary tract and metabolism products, other alimentary tract and metabolism products for veterinary use, Drugs for treatment of acetonemia


ATC Vet Code


QA16Q


5.1

Pharmacodynamic properties


The product is not pharmacologically active, and acts locally in the rumen of cattle by changing the surface tension of small gas bubbles trapped in foam, causing them to coalesce.

Simethicone (activated dimethicone, activated polymethylsiloxane) is used widely in the treatment of flatulence and for the elimination of gas or air foam from the gastrointestinal tract in man.

5.2

Pharmacokinetic properties


Simethicone is not absorbed following oral administration. Physiologically, silicones are extremely inert. It is considered to be non-toxic.


6.

PHARMACEUTICAL PARTICULARS

6.1

List of excipients


Sodium propyl hydroxybenzoate

Sodium methyl hydroxybenzoate

Glycerol monostearate (self emulsifying)

Dilute hydrochloric acid (for pH adjustment)

Water, purified

6.2

Incompatibilities


None known.

6.3

Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

6.4

Special precautions for storage


Shake the bottle before use.

Do not store above 25oC.

Do not freeze.

6.5

Nature and composition of immediate packaging


100 ml, low density, opaque, polyethylene bottle with a black, urea formaldehyde R6/22 mm cap, with an expanding polyethylene wad.

6.6

Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7.

MARKETING AUTHORISATION HOLDER


Dechra Limited

Snaygill Industrial Estate

Keighley Road

Skipton

North Yorkshire

BD23 2RW

United Kingdom


8.

MARKETING AUTHORISATION NUMBER


Vm 10434/4041

9.

DATE OF FIRST AUTHORISATION


30 March 1994

10.

DATE OF REVISION OF THE TEXT


September 2016


29 September 2016

Page 4 of 4